 Home > Biochemistry News > Biotechnology News > Innovative ADC therapy for ovarian cancer and triple-negative breast cancer enters the clinic

Innovative ADC therapy for ovarian cancer and triple-negative breast cancer enters the clinic

 Last Update: 2021-10-11
 Source: Internet
 Author: User

Tags

advanced water

advanced pavement group

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Today, ADC Therapeutics announced that ADCT-901, an antibody-conjugated drug (ADC) targeting kidney-associated antigen 1 (KAAG1), has completed the first patient administration in a phase 1 clinical trial for the treatment of certain patients with high unfinished needs.

ADCT-901 is produced by the anti-KAAG1 humanized monoclonal antibody, coupled with the cytotoxic molecule pyrrole benzodiazepine (PBD) dimer through a cathepsin cleavable linker

After ADCT-901 enters tumor cells, the released PBD can cross-link different DNA strands and hinder DNA replication and cell division

Image source: ADC Therapeutics official website

This open-label, dose-escalation and extended clinical trial will evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of ADCT-901

Reference materials:

[1] ADC Therapeutics Doses First Patient in Phase 1 Clinical Trial of ADCT-901 in Advanced Solid Tumors.

(The original text has been deleted)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Express treatment of ovarian cancer and triple-negative breast cancer, innovative ADC therapy entered the clinic

10-11

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Innovative ADC therapy for ovarian cancer and triple-negative breast cancer enters the clinic

Related Articles

Express treatment of ovarian cancer and triple-negative breast cancer, innovative ADC therapy entered the clinic